WVE

Wave is a clinical-stage RNA-medicines company with no approved products, and the financials read exactly like that: FY2025 revenue of $42.7M is collaboration money, not product sales, and it is inherently lumpy — it swung from $3.65M (FY2022) to $113M (FY2023) to $108M (FY2024) and back to $42.7M (FY2025), so the headline -60.5% 'decline' and the 25x P/S are essentially meaningless for valuing this name. What matters is the platform and the cash runway. The company states plainly in MD&A that it 'has never been profitable' and booked a $204.4M net loss, with operating margin of -504% and a -$187M operating cash burn — this is a binary, pipeline-driven story, not a fundamentals story.

The balance sheet is the reason this is a 'hold' and not an 'avoid.' Wave ended FY2025 with $602M cash (up 99.3%) against just $112M total liabilities and a clean 0.22x liabilities/equity. Against ~$187M annual burn that is roughly three years of runway, which buys time to read out the programs that matter: WVE-007, a GalNAc-siRNA targeting INHBE for obesity — the highest-value swing given the GLP-1/metabolic frenzy — plus WVE-006 (AATD) and WVE-008 (PNPLA3 liver disease), all using clinically validated GalNAc delivery rather than risky lipid-nanoparticle or gene-therapy approaches. Item 3 confirms no material legal proceedings, and the platform IP is described as 'strong and broad.'